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SUMMARY
We propose a dose-finding design for Phase I oncology trials where each new patient is assigned 
to the dose most likely to be the target dose given observed data. The main model assumption is 
that the dose-toxicity curve is non-decreasing. This method is beneficial when it is desirable to 
assign a patient to a dose as soon as the patient is enrolled into a study. To prevent assignments to 
doses with limited toxicity information in fast accruing trials we propose a conservative rule that 
assigns temporary fractional toxicities to patients still in follow-up. We also recommend using a 
safety rule with any dose-finding method.
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1. INTRODUCTION
The main objective of dose-finding trials in oncology is to learn about the dose-toxicity 
relationship of a drug and to estimate the maximum tolerated dose (MTD). The MTD is 
usually defined as the dose with a certain probability of dose limiting toxicity (DLT). We 
will use DLT and toxicity interchangeably. There is a long history of oncology dose-finding 
methods for estimating a dose with a certain mean response when outcome is binary [1, 2, 
3]. Recent reviews of dose-finding methods can be found in [4, 5]. Often it takes a long time 
to observe toxicity compared to accrual rate and a number of methods have been developed 
for dose-finding with delayed outcome [6, 7, 8]. In some trials, when the pace of disease is 
so rapid that a patient may succumb to the disease while waiting, it is desirable to enroll a 
patient into the trial and start treating as soon as possible. The method of Bekele et al. [8] 
solves the problem of fast accrual by prescribing when a trial should be halted as toxicity 
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rate at the current dose becomes uncertain. In TITE-CRM [6] the accrual is not halted and a 
new patient is assigned to the current MTD estimated based on all data including partial data 
from patients still in follow-up. As noted in [6] rapid accrual, especially in the beginning of 
the trial, may lead to assigning patients to doses with high toxicity rate when TITE-CRM is 
used. None of the existing dose-finding methods developed for delayed toxicity provide a 
conservative approach to enrollment in trials where a patient is assigned to a dose as soon as 
the patient is enrolled.
In most dose-finding designs that do not rely on an parsimonious model for the dose-toxicity 
relationship [1, 7, 9, 10, 11] the next assignment is determined based on the data at the 
current dose. We propose assigning patients at lower doses while the toxicity profile at 
higher doses is being explored. When assignments are being made to lower doses as well as 
the higher dose, it is no longer clear what dose is the current dose and therefore none of the 
above cited rules can be used for assignment. In this paper we describe a dose-finding 
method where the dose-assignment strategy is not tied to a current dose and the next 
assignment is made to the dose that is most likely to be the MTD. We refer to the new 
method as the Rapid Enrollment Design (RED). We describe this dose-assignment design in 
Section 2. In Section 3 we propose how to mitigate the uncertainty from patients still in 
follow-up when a new assignment is made. We give an example in Section 4. We compare 
designs in Section 5 and discuss the findings in Section 6.
2. DOSE-FINDING METHOD
Let D = {d1,…,dK} denote the set of ordered dose levels selected for a trial. Let T be the 
length of follow-up for toxicity. A subject’s response at dk has a Bernoulli distribution with 
parameter qk, where (q1,…,qK) is the vector of true toxicity rates at the K doses. We assume 
that q1,…,qK are non-decreasing, q1 ≤ … ≤ qK. Observations from different subjects are 
independent. The goal is to find dose dm ∈ D such that qm = Γ. If there is no such dose, the 
goal is to find the dose dm with mean response closest to Γ. We refer to Γ as the target DLT 
rate and dm as the target dose or the MTD.
First we consider the case where T is short compared to accrual rate and therefore toxicity 
responses from all patients are known when a new patient is enrolled. In the proposed 
design, each new patient is assigned to the dose with the highest probability of being the 
target dose given data available so far. Let n = (n1,…,nK) be the number of subjects assigned 
to each dose and m = (m1,…,mK) be the number of DLTs observed at each dose. Then the 
DLT rates at each dose can be estimated by simple proportions q̂j = mj / nj, j = 1,…,K. Since 
q1̂,…,q̂K might not be monotone we compute isotonic estimates  of DLT rates 
using the pool adjacent violator algorithm (PAVA) [12]. PAVA is described as follows. First 
we set , j =1,…, K. If q̂1 ≤…≤q̂K, then  and nothing else is needed. 
Otherwise, find the smallest k such that mk / nk > mk+1 / nk+1 and replace these two 
estimates with . We denote the estimate based on 
pooling data from doses dk and dk+1 by q̂k,k+1 with “dose” dk,k+1 and denominator nk,k+1 = 
nk + nk+1. Look again for a dose where the working isotonic estimate is greater than the 
working estimate at the next dose, and repeat the averaging and concatenation process until 
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isotonicity is actually obtained, that is, until . We note that the isotonic 
estimates obtained by PAVA are the maximum likelihood estimates assuming q1 ≤…≤qK. In 
the dose-assignment design described in the next paragraph when estimates 
are computed based on pooled data , we 
use the highest dose on the estimated plateau, dk+j, to represent the pooled doses if 
and the lowest dose on the estimated plateau, dk, if . To facilitate the Bayesian decision 
rule described below we assign the average number of DLTs (mk + …+ mk+j) / (j + 1) and 
the average sample size (nk + …+ nk+j) / (j + 1) of the pooled doses to that dose.
To compute the probability of a dose being the MTD we use Bayesian computations and 
assume Beta(α,β) prior on qj, j = 1, 2,…, K, the posterior distribution of qj conditional on 
outcome data is
The prior Beta(α,β) reflects the belief that there exists data from α +β patients, α patients 
with a DLT and β patients without a DLT. We use Jeffrey’s prior α = β = 0.5. This prior leads 
to decisions similar to the 3+3 design for small sample sizes when the target probability of 
DLT is around 0.2 and 0.25.
The design is based on the following rules. Let {d1,…,dk}, k ≤ K, be the set of doses with at 
least one patient assigned.
1. Initial escalation. Do not change the dose unless at least s patients are assigned to 
the current highest dose, k, and their toxicity outcomes observed (excep when the 
safety rule is invoked). The number s depends on the target rate Γ [13]. Cohort size 
s = 4 is recommended if Γ = 0.1, s = 3 if Γ = 0.25, and s = 1 if Γ = 0.5.
2. If  and at least s patients are assigned to dk, the next patient is assigned to dk+1 
(or dK if k = K).
3. If  and if there is a dose dj such that , the next patient is assigned to dj. 
Otherwise, let j, j ≤ k−1, be such that  and . Let probability πj reflect 
how close is the DLT rate at dj to Γ, πj = Pr{Γ−ε < qj < Γ + ε}. The next patient is 
assigned to the dose corresponding to the value πj or πj+1 that is higher.
4. Safety rule. Do not assign patients to a dose with Pr{qj > Γ} > 0.95, j = 1, 2,..., k. If 
Pr{q1 > Γ} > 0.95, the trial is stopped because the lowest dose is too toxic.
5. At the end of the trial the dose that would have been recommended for the next 
patient is selected as the estimated MTD. No dose is selected if the lowest dose is 
deemed too toxic by the stopping rule in 4).
In the rules above, ε, ε ≤ min(Γ,1-Γ), is a design parameter. We recommend ε = 0.05 
Robustness of this choice is discussed in Section 5.
Decision rules for two candidate doses, one with estimated DLT rate lower than Γ and one 
with rate higher than Γ, are shown in Table 1 for Γ = 0.25. The first column of the table 
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contains data yielding DLT proportion less than Γ = 0.25, and the second column DLT 
proportion higher than Γ = 0.25. The decision rule for each pair of the first and second 
column data is in column 3. For example, if 3 patients were enrolled at dose 1 with no DLTs, 
and 6 patients were enrolled at dose 2 with 2 DLTs, the decision rule for these data is to 
assign to the higher dose (seventh line from the bottom in Table 1). This is because the data 
at the two doses, (0/3, 2/6), yield π1 = 0.100 and π2 = 0.210.
To implement the RED we developed web-based software available at http://cancer.unc.edu/
biostatistics/program/ivanova/. The input is the number of DLTs at each dose, m = (m1,
…,mk), and the number of subjects at each dose n = (n1,…,nk). The program identifies two 
candidate doses dj and dj+1 using isotonic estimates and computes πj and πj+1. It also 
computes the probabilities that the DLT rates at the two doses are higher than Γ needed for 
the safety rule.
3. MITIGATING UNCERTAINTY FROM PATIENTS STILL IN FOLLOW-UP
In many Phase I oncology trials follow-up time is long compared to accrual rate. As 
mentioned in Section 2, when Γ = 0.25 we require that 3 patients complete follow-up at a 
previously untried dose before more patients can be assigned to that or a higher dose level. 
This however, does not fully resolve uncertainty about safety of future assignments. For 
example, if one out of the three patients had a DLT at the lowest dose, can we assign, say, 6 
more patients to that dose at once or is it too risky? We propose a simple way to mitigate this 
risk. A patient without a DLT who has been in the follow-up for time u and therefore has 
completed a fraction u/T of the total follow-up with 1−u / T of the follow-up still remaining 
is counted as a patient with 1−u / T of a temporary DLT. The total DLT count at a dose is the 
number of actual DLTs, m, plus the sum of temporary DLTs 1−ui / T, where the sum is over 
all the patients assigned at that dose that are still in follow-up. The denominator is the total 
number of patients at that dose irrespective of their follow-up time. These data are used to 
determine the next assignment according to the rules in Section 2.
For example, in a trial with the target Γ = 0.25 three patients have completed follow up at d1 
with one DLT and several patients are available to enroll. With 1 DLT out of 3, Pr{q1 > Γ} = 
0.67, therefore, since this probability is less than 0.95, at least one more patient can be 
enrolled. If one patient is enrolled, to mitigate potential DLT outcome from this patient, the 
data are augmented with 1 DLT at d1 yielding 2 DLTs out of 4 at d1 and Pr{q1 > Γ} = 0.87. 
Since this probability is less than 0.95 we can enroll one more patient. This assignment is 
less conservative than in the 3+3 design. The probability to observe 2 DLTs out of 4 patients 
if the true DLT rate is 0.25 is 0.21, that is, it is quite likely to see 2 DLTs in 4 patients. After 
augmenting 1/3 with 2/2, for two newly enrolled patients with u = 0 follow-up each, the DLT 
data at d1 are 3/5 yielding Pr{q1 > Γ} = 0.96, therefore we cannot assign more patients to d1 
at this point. After the two newly enrolled patients have been followed for, say, half the total 
follow-up time without a DLT, the data at d1 are 2/5, obtained by adding 1/3, 0.5/1 and 0.5/1, 
yielding Pr{q1 > Γ} = 0.79 and more patients can be enrolled. Patients are assigned to d1 
until the estimated DLT rate at d1 becomes lower than Γ = 0.25, at which point patients are 
assigned to d2.
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In another example, there are 3 patients enrolled at d1 with no DLTs, and 3 patients enrolled 
at d2 with 1 DLT observed in these 3 patients. The data at the two doses are (0/3, 1/3), 
corresponding to π1 = 0.10 and π2, therefore the next patient, patient seven, is assigned to d2. 
If patient eight is available at the time when patient seven is assigned, the augmented data 
are (0/3, 2/4), corresponding to π1 = 1.10 and π2 = 0.11, therefore, after checking the safety 
rule at d2, Pr{q2 > Γ} = 0.87, patient eight should be assigned to d2.
Note that for applying the stopping rule, Pr{q1 > Γ} > 0.95, at the lowest dose that might 
lead to terminating the trial, we only use real toxicities from patients who would have 
completed the follow-up by the time the analysis is performed and patients without toxicities 
who have completed the follow-up.
4. ACUTE MYELOID LEUKEMIA TRIAL EXAMPLE
Dose-finding trials in acute leukemia typically require a long follow-up for toxicity. This is 
because it is difficult to distinguish undue hematologic drug toxicity from the bone marrow 
effects of the disease itself. Often this requires follow-up for toxicity from an individual 
cycle of therapy that lasts 4–6 weeks rather than 3–4 weeks typical in solid tumors. In 
addition it is desirable to offer continuous enrollment in acute leukemia trials, since the pace 
of these leukemias is so rapid that the patient may succumb to the disease while waiting. Our 
new method was implemented in a dose-finding study of a new derivative of thalidomide for 
older adults with acute myeloid leukemia. Since the trial is ongoing, we used data from a 
recently completed Phase I trial [14] to illustrate the method. The trial investigated 
clofarabine in combination with gemtuzumab ozogamicin in relapsed or refractory acute 
myeloid leukemia patients. The DLT was defined as grade 3 or greater treatment-related 
toxicity lasting greater than 2 weeks or delay in hematologic recovery beyond 35 days from 
initiation of induction and not related to persistent or recurrent leukemia. Therefore the 
observation period for toxicity was 5 weeks from the start of therapy. The goal of the trial 
was to find a dose with the DLT rate of 0.26. The trial used the time-to-event cumulative 
cohort design [7] with an ad-hoc modification that allowed rapid enrollment with immediate 
assignment. We illustrate how the proposed dose-assignment algorithm would have worked 
if used in the gemtuzumab trial. We use patient enrollment times, their DLT outcomes and 
the time when a DLT has occurred. There were three patients who progressed or died 
between days 32 and 35 without a DLT, and therefore these patients were permanently 
censored for DLT before T = 35. In this illustration these patients are counted as patients 
with full follow-up of 35 days and no DLT. Dose assignments for all 20 patients are 
presented in Table 2. To make assignments in Table 2 coincide with those in the 
gemtuzumab trial we used the safety rule with 0.85 instead of 0.95. For example, after 
observing 2 DLTs in the first 4 patients at d2 in the gemtuzumab trial the next assignment 
was to d1. For these data, the posterior probability that the DLT rate is higher than the target 
of 0.26 is 0.86. Therefore if we set the cut-off for the safety rule at 0.85, the next assignment 
will be to d1. Similarly, after 5 DLTs were observed in 13 patients at d1 in the gemtuzumab 
trial, subsequent patients were assigned to d−1. The probability that the DLT rate at d1 was 
higher than the target of 0.26 was 0.85. Table 2 illustrates that our proposed design and the 
mitigation rule yielded rational dose assignments in a trial with rapid enrollment such as the 
gemtuzumab trial.
Ivanova et al. Page 5













5. COMPARISONS WITH OTHER DOSE-FINDING METHODS
5.1 Comparison with mTPI, the t-statistic designs and the CRM in trials with a short follow-
up time
First we considered the case where DLT outcome is known right away. We compared the 
RED with the modified toxicity probability interval (mTPI) method [11], the t-statistics 
design [10] and the CRM [2].
The mTPI is based on computing Bayesian posterior probabilities of the DLT rate being in 
certain intervals. Let dj be the current dose, that is, the dose the last patient was assigned to. 
Calculate three probabilities E = Pr{0 < qj < Γ − ε1}/(Γ − ε1), S = Pr{Γ − ε1 < qj < Γ + 
ε2}/(ε2 + ε1) and D = Pr{Γ + ε2 < qj < 1}/(1 − Γ − ε2). The next patient is assigned to dj+1 if 
E is the largest, to dj if S is the largest, and to dj−1 if D is the largest. If Pr{qj > Γ} > 0.95, j 
>1, patients are assigned to lower doses. If Pr{q1 > Γ} > 0.95 the trial is stopped. The 
estimated MTD is the dose with the estimated DLT rate closest to Γ.
The t-statistics method is a dose-finding design in which the t-statistic, t, to test the 
hypothesis that the mean at the current dose is equal to the target, is computed at each step. 
The next patient is assigned to the current dose if −Δ < t < Δ, otherwise the dose is reduced 
or increased depending on the sign of t. Here Δ is a design parameter and Δ = 1 is 
recommended. In the t-statistic design to estimate the target dose after the trial for the new 
design, we first obtained the isotonic estimates of DLT rates. The dose with the estimated 
DLT rate closest to Γ is the estimated MTD. If there are two or more such doses, the highest 
dose with the estimated DLT rate below Γ is chosen. If all the estimated rates at these doses 
are higher than Γ, the lowest of these doses is chosen.
To describe the CRM, let xi be the dose level received by subject i, xi ∈ D, and yi = 1 if the 
ith subject had a DLT and 0 otherwise. In the CRM [2], the calculation of posterior mean of 
parameter θ at the time when (n+1)th subject enters the trial is based on the likelihood:
where  and b1 < … < bK is a set of positive constants. We used the prior and 
(b1,…,bK)= (0.05, 0.1, 0.2, 0.3, 0.5, 0.7) as in [11] with our six-dose scenarios.
To compare designs we used scenarios from [6] and [11]. Here we show results for four of 
the five scenarios from [6] and one scenario from [11] that we reduced to a six-dose scenario 
by removing the two highest doses. That is, scenario 2 from [6] was replaced with a more 
interesting scenario from [11]. Results for the remaining scenarios are available from the 
authors. Simulations were performed in R and comparison was made based on 4000 
simulation runs for each scenario. The target DLT rate was Γ = 0.2. Patients were assigned 
in cohorts of 3 in all designs. Note that all designs can be used with any number of patients 
per cohort. In the RED we set α = β = 0.5 and ε = 0.05. In mTPI design the prior parameters 
were α = β = 1 as in [11]. To make all the designs comparable we used the safety rule, rule 
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4) from Section 2, with the t-statistic design and the CRM (CRM+S) not only with the mTPI 
method and the RED. We also simulated the CRM without the safety rule. Simulation results 
are displayed in Table 3 and summary measures of these results in Table 5.
Overall mTPI, t-statistic, the RED and the CRM+S perform very similarly as far as average 
targeting precision and the average overdose (Table 3 and Table 5). In scenario 2 adopted 
from [11], the DLT probability at d2 is 0.05 and the DLT probability at d3 is 0.50. The CRM 
recommended d3 in 34% of all trials. This is the consequence of relying solely on a 
parsimonious model. To correct that, we simulated the CRM with the safety rule (CRM+S). 
The addition of the safety rule reduced the proportion of trials where the unsafe dose d3 was 
selected to 10%, however, it also worsened the CRM performance as far as the true MTD 
selection across scenarios, from 51% on average to 43% (Table 5). Since safety is important 
the CRM with the safety rule might be a good alternative to the CRM.
We investigated the robustness of the new design with respect to parameter ε. We performed 
simulations with values of ε in the range (0.01, 0.1) and obtained results very similar to ε = 
0.05.
5.2 Comparison with TITE-CRM when the follow-up for DLT is long
Cheung and Chappell [6] proposed a time-to-event modification of the CRM, TITE-CRM, 
for dose-finding trials where follow-up for DLT is long. In clinical trials that require long 
follow-up times, the toxicity rate at dose xi is defined as the probability of observing toxicity 
at xi during a time period of length T after initiation of therapy. Data for the ith subject, i = 
1,…, r, when (r+1)th subject is assigned to a treatment, consists of dose xi, toxicity indicator 
yi and the time ui that has elapsed from the time of the ith subject’s treatment assignment to 
the time of the (r+1)th subject’s treatment assignment. For TITE-CRM, Cheung and 
Chappell [6] suggested the weighted likelihood
where wi is the weight assigned to the ith observation prior to the entry of the (r+1)th 
subject. For example, setting wi = min(ui / T,1) reflects an assumption that the density of 
time to toxicity is flat in (0,T).
We compared the performance of the TITE-CRM and the RED for delayed toxicity outcome 
via simulations. In the RED the uncertainty from patients still in follow-up was mitigated as 
described in Section 3 (RED with mitigation). In the TITE-CRM, a patient who has been 
followed for a fraction w of full follow-up time T and has not had a DLT yet is contributing 
roughly as a fractional patient (w of a patient) without a DLT. On the other hand, in our 
approach such a patient is contributing as 1 patient with (1 − w) DLTs. We simulated the 
original CRM with our mitigation rule from Section 3 (CRM with mitigation) as well.
Table 4 displays comparisons of the designs in a trial with a 35-day follow up for DLT with 
Table 5 displaying summary results. A new patient is enrolled on Monday every two weeks. 
For patients with DLT, time to DLT was generated as a uniform random variable on (0,35). 
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Simulating time to DLT using exponential distribution yielded very similar selection 
probabilities for all designs. The performance of the TITE-CRM in the five scenarios does 
not differ much from the CRM where our conservative toxicity mitigation rule was used to 
“impute” toxicity of patients still in follow-up (Table 4 and Table 5). The TITE-CRM 
selected unsafe doses in 16% of the trials on average and the CRM with our mitigation rule 
selected unsafe doses in 15% of the trials (Table 5). Similar performance of the two methods 
is due to the fact that the accrual is that very rapid compared to the follow-up length and, 
therefore, the way how DLTs are “imputed” is affecting the escalation considerably only in 
the beginning of the trial when not much DLT information is available. In contrast, an 
addition of the safety rule to the CRM with mitigation reduced the selection of unsafe doses 
to 6% (Table 5). The RED with mitigation performed similarly to the CRM with the safety 
rule and mitigation as far as average targeting precision and the average overdose (Table 5).
Interestingly, the CRM with mitigation performed much better in scenario 5 compared to the 
TITE-CRM. This scenario is an example of a scenario where CRM might not converge to 
the true MTD, d5, and converges to d4 instead in a large proportion of trials [15]. For the 
CRM with mitigation the probability of correctly selecting the true MTD in scenario 5 was 
0.50 compared to 0.33 for the TITE-CRM (Table 4). This might be because the CRM with 
mitigation yields low estimates of the DLT probability at d4 in the beginning of the trial 
allowing the CRM to escalate to the true MTD at d5.
The length of a trial with rapid enrollment is at most 65 weeks. For comparison in a trial 
with the same accrual pattern where we wait until each cohort of 3 patients is fully followed 
before we enrolled the first patient from the next cohort, the trial length is 109 weeks. The 
results of the latter are the same as those presented in Table 3. Simulation summary in Table 
5 shows that the RED and the CRM+SCRM+S with toxicity mitigation provide good 
estimation of the MTD without exposing patients to doses with high DLT rates in trials with 
long follow-up for toxicity when patients are enrolled at any time.
6. DISCUSSION
We proposed a new method to assign patients to doses in a Phase I oncology trial and a 
method to mitigate uncertainty of unobserved toxicities from patients still in follow-up. Ji 
and Wang [16] recently compared the mTPI and the 3+3 design [17] and showed that mTPI 
can identify the correct MTD better and also assigns fewer patients to the toxic doses above 
the MTD. Our new method performs similar to mTPI but also has the flexibility to 
accommodate rapid enrollment in trials with long follow-up for toxicity.
Our simulations of the TITE-CRM showed that in trials with delayed toxicity outcome the 
TITE-CRM selects unsafe doses relatively often. The classical CRM with our toxicity 
mitigation rule and the safety rule performs much better compared to the TITE-CRM in 
trials with delayed toxicity outcome. Another advantage is that while the TITE-CRM 
requires the TITE-CRM specific software, the CRM with toxicity mitigation can be 
implemented using the CRM software (though one will need to add a safety rule). Of note, 
we did not study the convergence of the CRM with addition of the mitigation and safety 
rules.
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The main purpose of the mitigation rule we proposed is to guide dose assignments when 
there is little or no information available at a dose. When many patients have been enrolled 
at a dose, data from these patients overwhelms temporary toxicities assigned by the 
mitigation rule to patients still in follow-up and the mitigation rule does not play much of a 
role in dose assignment. We took a conservative approach to mitigate uncertainty of 
unobserved toxicities as this is often a choice of Phase I investigators. The new mitigation 
approach allows eliminating a set of rules we sometimes see in Phase I protocols. These 
rules prescribe when to wait to enroll a patient, when to enroll a patient and to what dose the 
patient should be assigned. Such rules can be cumbersome, especially if enrolling patients is 
allowed (usually at lower doses) before an initial cohort of patients at each new dose is fully 
followed. Our new dose assignment rule and the method of assigning temporary toxicity to 
patients still in follow-up eliminates the need for these rules. After temporary toxicities are 
assigned to patients still in follow-up, the assignment follows the primary design as if there 
is no delay in observing the DLT outcome. A web-based program is available to identify a 
dose for the next assignment given trial data.
We also developed a dose-assignment design similar to the RED that can be used for dose-
finding with continuous outcome or where toxicity score or continuous biomarker is used in 
place of binary toxicity outcome [18].
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Table 1
Dose allocation decision based on the posterior probability at two candidate doses dj and dj+1. Target 
probability is Γ = 0.25. The observed toxicity rate at dj is less than Γ and the observed toxicity rate at dj+1 is 
higher than Γ. Data at each dose is the number of DLTs over the number of patients assigned to the dose. The 
entry 0/1:3, for example, indicates one of the three possibilities: 0 DLTs were observed out of 1 or 2 or 3 
patients.
Observed data at dj Observed data at dj+1 Decision
1/4:9, 2/8:12, 3/12 1/3, 2/5 Lower Dose
1/4:10, 2/8:12, 3/12 3/7, 5/12 Lower Dose
2/8:12, 3/12 2/7, 3/9, 4/11 Lower Dose
1/4:7, 2/8:12, 3/12 3/8 Lower Dose
1/5:6, 2/8:12, 3/12 2/6 Lower Dose
2/9:10, 3/12 3/10 Lower Dose
3/12 3/11 Lower Dose
1/4:8, 2/8:12, 3/12 4/10 Lower Dose
2/8:11, 3/12 4/12 Lower Dose
1/4:11, 2/8:12, 3/12 4/9 Lower Dose
0/1:2, 1/4:12, 2/8:12, 3/12 1/2, 2/4, 5/11 Lower Dose
0/1:3, 1/4:12, 2/8:12, 3/12 3/6 Lower Dose
0/1:4, 1/4:12, 2/8:12, 3/12 4/8 Lower Dose
0/1:5, 1/4:12, 2/8:12, 3/12 5/10, 6/12 Lower Dose
0/1:8, 1/4:12, 2/8:12, 3/12 6/11 Lower Dose
0/3:12 1/2, 2/4, 5/11 Higher Dose
0/4:12 3/6 Higher Dose
0/5:12 4/8 Higher Dose
0/2:12, 1/10:12 1/3, 2/5 Higher Dose
0/2:12, 1/11:12 3/7, 5/12 Higher Dose
0/2:12, 1/4:12 2/6:7, 3/9, 4/11 Higher Dose
0/1:12, 1/8:12 3/8, 4/10 Higher Dose
0/1:12, 1/4:12, 2/8:12 3/10:11 Higher Dose
0/1:12, 1/4:12, 2/12 4/12 Higher Dose
0/1:12, 1/12 4/9 Higher Dose
0/6:12 5/10, 6/12 Higher Dose
0/9:12 6/11 Higher Dose
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Table 5
Summary measures for Tables 4 and 5. The average MTD targeting precision (Average Targeting Precision) is 
the average of the probabilities of correctly recommending the true MTD in scenarios 1, 3, 4 and 5. The 
average overdose measure (Average Overdose) is the probability of selecting a dose with the DLT rate of 0.4 













CRM with mitigation 0.44 0.15
CRM+S with mitigation 0.42 0.06
RED with mitigation 0.41 0.07
Stat Med. Author manuscript; available in PMC 2017 July 10.
